Blontuvetmab

Last updated March 15, 2019

Blontuvetmab
Monoclonal antibody
Type	Whole antibody
Target	CD20
Clinical data
Trade names	Blontress
Synonyms	AT-004
ATC code	none
Identifiers
CAS Number	1608112-78-2
ChemSpider	none
UNII	49OD1NGH0Z
Chemical and physical data
Formula	C₆₄₆₂H₉₉₈₄N₁₇₁₂O₂₀₁₂S₄₆
Molar mass	145.32 kDa

Blontuvetmab (AT-004) (INN, trade name Blontress) is a veterinary monoclonal antibody.^[1]^[2]

This drug was developed by Aratana Pharmaceuticals.

References

↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Blontuvetmab, American Medical Association .
↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab ^§ Ascrinvacumab ^§ Cixutumumab ^§ Conatumumab ^§ Daratumumab Drozitumab ^§ Duligotumab ^§ Dusigitumab ^§ Enfortumab vedotin ^§ Enoticumab ^§ Figitumumab ^§ Ganitumab ^† Glembatumumab vedotin ^† Intetumumab ^§ Ipilimumab Iratumumab ^§ Istiratumab Icrucumab ^§ Lexatumumab ^§ Lucatumumab ^§ Mapatumumab ^§ Narnatumab ^§ Necitumumab Nesvacumab ^§ Ofatumumab Olaratumab ^† Panitumumab Patritumab ^§ Pritumumab ^§ Radretumab ^§ Ramucirumab Rilotumumab ^† Robatumumab ^§ Seribantumab ^§ Tarextumab ^§ Teprotumumab ^† Tovetumab ^§ Vantictumab ^§ Vesencumab ^§ Votumumab ^§ Zalutumumab ^† "-melu-" (melanoma) Flanvotumab ^§
Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Lilotomab Minretumomab Mitumomab Moxetumomab pasudotox ^† Naptumomab estafenatox Nofetumomab merpentan Pemtumomab ^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox
Chimeric ("-tuxi-")	Amatuximab ^§ Bavituximab ^§ Brentuximab vedotin Carotuximab ^† Cetuximab Derlotuximab biotin ^§ Dinutuximab Ensituximab ^§ Futuximab ^§ Girentuximab ^† Indatuximab ravtansine ^§ Isatuximab ^† Loncastuximab tesirine Margetuximab ^† Rituximab ^# Siltuximab Ublituximab ^† "-mexi-" (melanoma): Ecromeximab ^§
Humanized ("-tuzu-")	Abituzumab ^§ Alemtuzumab Bevacizumab Bivatuzumab mertansine ^§ Brontictuzumab ^§ Cantuzumab mertansine ^§ Cantuzumab ravtansine ^§ Citatuzumab bogatox ^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab ^§ Demcizumab ^§ Dalotuzumab ^§ Denintuzumab mafodotin ^§ Elotuzumab Emactuzumab ^§ Emibetuzumab ^§ Enoblituzumab ^§ Etaracizumab ^§ Farletuzumab ^§ Ficlatuzumab ^§ Flotetuzumab ^§ Gemtuzumab ozogamicin ^‡ Imgatuzumab ^§ Inotuzumab ozogamicin ^† Labetuzumab ^§ Lifastuzumab vedotin ^§ Lintuzumab ^§ Lorvotuzumab mertansine ^§ Lumretuzumab ^§ Matuzumab ^§ Milatuzumab ^§ Nimotuzumab ^† Obinutuzumab Ocaratuzumab ^§ Otlertuzumab ^§ Onartuzumab ^§ Oportuzumab monatox ^† Parsatuzumab ^§ Pertuzumab Pinatuzumab vedotin ^§ Polatuzumab vedotin ^† Rosmantuzumab Rovalpituzumab tesirine ^† Sacituzumab govitecan ^† Sibrotuzumab ^§ Simtuzumab ^§ Tacatuzumab tetraxetan ^§ Tigatuzumab ^§ Trastuzumab Tucotuzumab celmoleukin ^§ Vandortuzumab vedotin ^§ Vanucizumab ^§ Veltuzumab ^§ Vorsetuzumab mafodotin ^§ CBR96-doxorubicin immunoconjugate PankoMab "-gozu-" (ovarian tumor) Sofituzumab vedotin ^§
Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab ^§
Chimeric + humanized ("-tuxizu-")	Depatuxizumab mafodotin ^† Duvortuxizumab Ontuxizumab ^§
Veterinary ("-tuvet-")	Blontuvetmab ^§ Tamtuvetmab ^§

^# WHO-EM
^‡ Withdrawn from market
Clinical trials:
- ^† Phase III
- ^§Never to phase III

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.